

## Prescribing Clinical Network

<b>Policy Statement</b>	Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
<b>Policy Number</b>	PCN 375-2018
<b>Date of Issue</b>	November - 2018
<b>Review Date:</b>	November - 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<b>Recommendations:</b> <p>The Prescribing Clinical Network recommends Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs in line with NICE TA537 (August 2018).</p> <p>Ixekizumab for this indication will be considered as <b>RED</b> on the traffic light status (treatment should be initiated and continued by specialist clinicians)</p> <p>Ixekizumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.</p>	
<b>Key Considerations:</b> <ul style="list-style-type: none"> <li>NICE TA537 (August 2018) – Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs  <a href="https://www.nice.org.uk/guidance/ta537/resources/ixekizumab-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards-pdf-82606905979333">https://www.nice.org.uk/guidance/ta537/resources/ixekizumab-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards-pdf-82606905979333</a> </li> </ul>	
<b>Date taken to Prescribing Clinical Network</b>	7 <sup>th</sup> November 2018
<b>Agreed by PCN members</b>	19 <sup>th</sup> November 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG